» Articles » PMID: 12359622

Therapeutic Effect of the Endogenous Fatty Acid Amide, Palmitoylethanolamide, in Rat Acute Inflammation: Inhibition of Nitric Oxide and Cyclo-oxygenase Systems

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 2002 Oct 3
PMID 12359622
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

1. The anti-inflammatory activity of the endogenous fatty acid amide palmitoylethanolamide and its relationship to cyclo-oxygenase (COX) activity, nitric oxide (NO) and oxygen free radical production were investigated in the rat model of carrageenan-induced acute paw inflammation and compared with the nonsteroidal anti-inflammatory drug (NSAID) indomethacin. 2. Palmitoylethanolamide (1, 3, 5, 10 mg kg(-1); p.o.) and indomethacin (5 mg kg(-1); p.o.) were administered daily after the onset of inflammation for three days and the paw oedema was measured daily; 24 h after the last dose (fourth day) the rats were killed and the COX activity and the content of nitrite/nitrate (NO(2)(-)/NO(3)(-)), malondialdehyde (MDA), endothelial and inducible nitric oxide synthase (eNOS and iNOS) were evaluated in the paw tissues. 3. Palmitoylethanolamide had a curative effect on inflammation, inhibiting the carrageenan-induced oedema in a dose- and time-dependent manner. This effect was not reversed by the selective CB(2) receptor antagonist (N-[(1S)-endo-1,3,3-trimethylbicyclo[2.2.1]heptan-2yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)pyrazole-3 carboxamide) (SR144528), 3 mg kg(-1) p.o. On the fourth day after carrageenan injection, COX activity and the level of NO(2)(-)/NO(3)(-), eNOS and MDA were increased in the inflamed paw, but iNOS was not present. Palmitoylethanolamide (10 mg kg(-1)) and indomethacin markedly reduced these increases. 4. Our findings show, for the first time, that palmitoylethanolamide has a curative effect in a model of acute inflammation. The inhibition of COX activity and of NO and free radical production at the site of inflammation might account for this activity.

Citing Articles

Palmitoylethanolamide causes dose-dependent changes in brain function and the lipidome.

Balaji S, Woodward T, Richter E, Chang A, Otiz R, Kulkarni P Front Neurosci. 2024; 18:1506352.

PMID: 39664446 PMC: 11631868. DOI: 10.3389/fnins.2024.1506352.


Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases.

Ramer R, Hinz B Cells. 2022; 11(24).

PMID: 36552866 PMC: 9777118. DOI: 10.3390/cells11244102.


Endocannabinoid levels in peripheral blood mononuclear cells of multiple sclerosis patients treated with dimethyl fumarate.

Sanchez-Sanz A, Posada-Ayala M, Sabin-Munoz J, Fernandez-Miranda I, Aladro-Benito Y, Alvarez-Lafuente R Sci Rep. 2022; 12(1):20300.

PMID: 36434122 PMC: 9700785. DOI: 10.1038/s41598-022-21807-y.


Effects of Ultramicronized Palmitoylethanolamide on Mitochondrial Bioenergetics, Cerebral Metabolism, and Glutamatergic Transmission: An Integrated Approach in a Triple Transgenic Mouse Model of Alzheimer's Disease.

Bellanti F, Naik Bukke V, Moola A, Villani R, Scuderi C, Steardo L Front Aging Neurosci. 2022; 14:890855.

PMID: 35686025 PMC: 9170916. DOI: 10.3389/fnagi.2022.890855.


Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans.

Landolfo E, Cutuli D, Petrosini L, Caltagirone C Biomolecules. 2022; 12(5).

PMID: 35625595 PMC: 9138306. DOI: 10.3390/biom12050667.


References
1.
Lambert D, Di Marzo V . The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic?. Curr Med Chem. 1999; 6(8):757-73. View

2.
Osborne M, Coderre T . Effects of intrathecal administration of nitric oxide synthase inhibitors on carrageenan-induced thermal hyperalgesia. Br J Pharmacol. 1999; 126(8):1840-6. PMC: 1565961. DOI: 10.1038/sj.bjp.0702508. View

3.
Griffin G, Tao Q, Abood M . Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther. 2000; 292(3):886-94. View

4.
Ross R, Brockie H, Pertwee R . Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur J Pharmacol. 2000; 401(2):121-30. DOI: 10.1016/s0014-2999(00)00437-4. View

5.
Malfait A, Gallily R, Sumariwalla P, Malik A, Andreakos E, Mechoulam R . The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000; 97(17):9561-6. PMC: 16904. DOI: 10.1073/pnas.160105897. View